Psoriasis

Janssen has announced that the National Institute for Health and Clinical Excellence (NICE), has recommended Stelara® (ustekinumab) in its Final Appraisal Determination (FAD)1 as...  

For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066*.  

Celgene Corporation has announced that results from its ongoing phase III LIBERATE trial evaluating Otezla® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4...  

Only a single treatment produced what researchers describe as 'rapid, substantial, and durable clinical...  

Novartis Pharmaceuticals UK Limited (Novartis) has announced that Cosentyx (secukinumab) is available for use in the UK for the treatment of moderate to severe plaque psoriasis in adults who...  

Immunotherapy with natural signaling substance relieves skin conditionA three-character code brings relief to patients with psoriasis and sheds light on complex...  

People with psoriasis and their health care providers will have the opportunity to participate in research that aims to improve treatments and disease outcomes when the first independent U.S.  

PsA is a common form of inflammatory form of arthritis causing pain and stiffness in joints and tendons that can lead to joint damage.  

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company ('Provectus'), has announced that it has opened recruitment for its phase 2 mechanism...  

Case Western Reserve scientists have taken a huge leap toward identifying root causes of psoriasis, an inflammatory skin condition affecting 125 million people around the world.  

The U.S. Food and Drug Administration has approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.  

Celgene UK has announced that the European Commission has licensed Otezla, the Company's oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic...  

The annual U.S. cost of psoriasis, a chronic inflammatory skin condition, was estimated to be between $112 billion and $135 billion in 2013, according to a review article published online by...  

LEO Pharma announced it has submitted a New Drug Application to the US Food and Drug Administration (FDA) for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the...  

Study finds many commonalities, but no evidence of excess mortality.  

Psoriasis is a long-term inflammatory skin condition that can markedly reduce the quality of life of affected individuals. Treatments taken by mouth (oral treatments), such as methotrexate, ciclosporin, and acitretin, are commonly prescribed to people with moderate to severe psoriasis. Oral fumaric acid esters (FAE) are licensed for the treatment of psoriasis in Germany but remain unlicensed in most other countries. This means that there are different treatment options offered to people in different countries.